Skip to content

Retinal Organoids

Our retinal organoids contains all cell found in the human retina and hold incredible promise for the future of medicine, offering hope for new treatments and personalized approaches to treat patients with retinal dystrophies.

We have optimized and fine-tunned procedures for the generation of cutting-edge retinal organoid models.


Neural retinal progenitor cell marker

Retinal ganglion cell marker


Key features of our retinal organoid models:

  • Reproducibility with the right representation and composition of all retinal cell types
  • Low batch to batch variation
  • Enable long term modelling
  • Origin: Generated from healthy donor tissues and patients carrying disease-associated gene mutations (e.g., PRPF31, CLN3).
  • Age: Available at customizable time points.

Healthy Retinal Organoids

Retinal organoids (ROs) derived from human induced pluripotent stem cells (iPSC) largely recapitulate critical features of in vivo retinal development, permitting the study of retinogenesis, disease modeling, and therapeutic development.

Patient-derived retinal organoid models

DAY 16
DAY 60

Disease retinal models (patient derived)

Patient-derived retinal organoids are relevant physiological in­ vitro preclinical models, offering new translational approaches to the diagnosis and treatment of diseases causing vision loss.

Modeling retinitis pigmentosa

  • Retinitis pigmentosa (RP) is a genetic disease caused by loss of photoreceptor cells in the retina, gradually leading to vision loss.
  • One of the most common forms of RP is RP11, caused by mutations in the PRPF31
  • Prpf31 deficient animal models either do not recapitulate the human retinitis pigmentosa (RP) phenotype, or are embryonic lethal, or only display late-onset visual deficiencies.

Figure 1. Normal retina (upper left) and retina of a patient affected by retinitis pigmentosa (RP, bottom left). And visual impairment experienced by RP11 patients (bottom right) compared to normal vision (upper right).

Back To Top